Henry Schein, Inc. (HSIC) is a publicly traded company in the Healthcare — Medical - Distribution industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services.
Analysis Summary
Henry Schein, Inc. reported revenue of $13.18B in the most recent fiscal year, growing at a 5-year CAGR of 5.4%. Net income reached $398.0M, with a -0.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 30.3%, operating margin 5.7%, net margin 3.0%. Free cash flow grew at 0.8% CAGR over 5 years.
At the current price of $86.77, HSIC trades at a P/E of 25.08 and an ROE of 12.37%. Market capitalisation stands at $9.9B.
Balance sheet quality for HSIC: current ratio of 1.4, net debt of $3.53B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $573.0M represents 144% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $86.77 |
| Market Cap | $9.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 25.08 |
| Price / Book | 3.12 |
| EV / EBITDA | 13.13 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 12.37% |
| Return on Invested Capital | 6.47% |
| Return on Assets | 3.54% |
| Gross Margin | 30.31% |
| Operating Margin | 5.69% |
| Net Margin | 2.96% |
Financial Health
| Debt / Equity | 1.21 |
| Current Ratio | 1.32 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 2.80 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HSIC | Henry Schein, Inc. | $9.9B | 25.08 | 3.12 | 12.4% |
| MASI | Masimo Corporation | $9.4B | 124.97 | 11.91 | 9.1% |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| GRFS | Grifols, S.A. | $6.5B | 14.21 | 1.17 | |
| GMED | Globus Medical, Inc. | $10.1B | 19.14 | 2.16 | |
| DVA | DaVita Inc. | $12.1B | |||
| ATR | AptarGroup, Inc. | $8.0B | |||
| BIO | Bio-Rad Laboratories, Inc. | $10.2B | 45.63 | 1.42 | 3.2% |
Price Performance
| 1 month | -2.76% |
| 3 months | +8.57% |
| Year-to-date | +14.81% |
| 1 year | +28.80% |
| 3 years | +17.16% |
52-Week Range
| 52-week High | $92.18 |
| 52-week Low | $61.95 |
| Avg Volume (90d) | 1.3M |
Related companies: ATR · AVTR · BIO · DVA · GMED · GRFS · HALO
Explore sector: Healthcare · Medical - Distribution
More sections of HSIC: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks